Skip to main content

Table 2 One-year outcomes

From: Treatment outcomes of retinal vein occlusion in clinical practice in Nepal

  CRVO BRVO p value
Patients, n 39 60  
Baseline VA logMAR, mean (SD) 1.13 (0.61) 0.75 (0.42) 0.001
Final VA logMAR, mean (SD)* 0.92 (0.75) 0.4 (0.4) < 0.001
Change VA logMAR*,
mean (95% CI)
−0.2
(− 0.43, 0.02)
−0.35
(− 0.46, − 0.23)
0.25
VA ≤ 0.3 logMAR, % (baseline/final*) 10 / 36 20 / 63 0.01
VA ≥ 1 logMAR, % (baseline/final*) 59 /47 37 /12 < 0.001
Improvement ≥3 lines*, % 32 60 0.37
Worsening ≥3 lines*, % 8 7 0.31
Baseline IOP mmHg, mean (SD) 19 (11) 16 (3) 0.07
Final IOP mmHg, mean (SD)* 17 (2) 15 (5) 0.05
Change IOP mmHg*,
mean (95% CI)
−3
(−6, 0)
−2
(−4, −1)
0.64
Baseline CST μm, mean (SD) 519 (213) 423 (151) 0.02
Final CST μm, mean (SD)* 343 (160) 281 (133) 0.09
Change CST μm*,
mean (95% CI)
−184
(−276, −91)
− 114
(− 189, −40)
0.24
Injections α, median (Q1, Q3) 2 (1, 3) 2 (1, 3) 1
Additional Macular Laser, n 0 2 0.52
Additional Triamcinolone, n 2 2 0.65
Additional PRP/Sectoral Laser, n 16 15 0.17
  1. n Number, VA Visual Acuity, SD Standard Deviation, CI Confidence Interval, CST Central Subfield Thickness, Q1 First Quantile, Q3 Third Quantile, PRP Panretinal photocoagulation, * Last observation carried forward for lost to follow-up, α Number of bevacizumab injections
\